Hugel, Inc.

KOSDAQ:A145020 주식 보고서

시가총액: ₩3.2t

Hugel 과거 수익 실적

과거 기준 확인 5/6

Hugel은 연평균 16.9%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 증가했으며, 연간 7.2%였습니다. 매출은 연평균 11.9%의 비율로 증가했습니다. Hugel의 자기자본이익률은 14.6%이고 순이익률은 32.4%입니다.

주요 정보

16.9%

수익 성장률

19.9%

EPS 성장률

Biotechs 산업 성장11.7%
매출 성장률11.9%
자기자본 수익률14.6%
순이익32.4%
다음 실적 업데이트06 Nov 2024

최근 과거 실적 업데이트

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29
Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29
Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

Oct 19
Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Sep 13
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Aug 09
There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Jun 10
Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Apr 19
Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29
Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Mar 05
Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Mar 04
Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

Mar 19
Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Feb 25
What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Feb 04
Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Jan 17
The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29
Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

Dec 14
Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Nov 24
How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

수익 및 비용 분석

Hugel 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

KOSDAQ:A145020 수익, 비용 및 수입 (KRW Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24343,494111,174106,7548,952
31 Mar 24329,62697,506111,9309,927
31 Dec 23319,70093,076109,47011,015
30 Sep 23316,24578,490112,43414,330
30 Jun 23302,10566,435111,26614,722
31 Mar 23284,41259,834104,16514,902
31 Dec 22281,67560,55894,51415,078
30 Sep 22253,83862,66582,95913,833
30 Jun 22235,49955,51172,12613,284
31 Mar 22229,67954,98165,36012,366
31 Dec 21231,85956,50661,67512,624
30 Sep 21241,63464,58259,82311,853
30 Jun 21243,36954,22256,15114,060
31 Mar 21233,60454,61551,13515,879
31 Dec 20211,03841,99249,32615,741
30 Sep 20197,62939,72850,50714,950
30 Jun 20194,69939,91054,20312,849
31 Mar 20196,70736,81557,97011,034
31 Dec 19204,56844,61261,52010,226
30 Sep 19209,36047,99366,02210,433
30 Jun 19193,15460,76368,3609,514
31 Mar 19185,73264,10465,7528,823
31 Dec 18182,39269,73660,9647,750
30 Sep 18173,68875,55249,9816,930
30 Jun 18180,32269,98539,3746,653
31 Mar 18183,61373,91834,2027,038
31 Dec 17182,08572,82730,9336,922
30 Sep 17169,77867,66526,9126,878
30 Jun 17161,01163,02226,7185,811
31 Mar 17145,78656,09625,9194,436
31 Dec 16124,18943,27325,1874,065
30 Sep 16108,88336,54023,3503,372
30 Jun 1694,23173,09322,3032,919
31 Mar 1680,09839,21618,7953,884
31 Dec 1565,06633,92916,4253,156
30 Sep 1559,32833,92414,9403,087
30 Jun 1549,887-12,90411,9633,616
31 Dec 1440,35013,15010,6521,942
31 Dec 1329,1707,3077,1752,220

양질의 수익: A145020 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: A145020 의 현재 순이익 이익률 (32.4%) 작년보다 높습니다 (22%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: A145020 의 수입은 지난 5년 동안 매년 16.9% 씩 증가했습니다.

성장 가속화: 지난 1년간 A145020 의 수익 증가율( 67.3% )은 연간 평균( 16.9% 초과합니다. ).

수익 대 산업: 지난 1년간 A145020 수익 증가율( 67.3% )은 Biotechs 업계 6.1% 초과했습니다.


자기자본 수익률

높은 ROE: A145020 의 자본 수익률( 14.6% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기